Skip to main content
Premium Trial:

Request an Annual Quote

GenomeDx Biosciences to Pay $2M to Settle Allegations of Improper Medicare Billing

NEW YORK (GenomeWeb) – GenomeDx Biosciences has agreed to pay $1.99 million to settle charges that it improperly billed Medicare for its Decipher Biopsy prostate cancer genomic classifier, the US Attorney's Office for the Southern District of California announced on Monday.

The federal government alleged that GenomeDx submitted claims to Medicare between September 2015 and June 2017 for the Decipher test that were not medically reasonable and necessary, in violation of the False Claims Act. According to the US Attorney's Office, the patients that GenomeDx submitted the claims on behalf of did not have risk factors that required the test. Specifically, they did not have pathological stage T2 disease with a positive surgical margin, pathological stage T3 disease, or rising prostate-specific antigen levels after an initial PSA nadir.

The allegations arose from a whistleblower lawsuit filed by two former employees of GenomeDx, Stephanie LaFleur and Corrine Vause, who will receive about $350,000 of the $1.99 million settlement.

GenomeDx is based in Vancouver, British Columbia, but also has operations in San Diego. The company did not respond to a request for comment. 

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.